AT223704T - Method for producing wax matrices - Google Patents

Method for producing wax matrices

Info

Publication number
AT223704T
AT223704T AT93922628T AT93922628T AT223704T AT 223704 T AT223704 T AT 223704T AT 93922628 T AT93922628 T AT 93922628T AT 93922628 T AT93922628 T AT 93922628T AT 223704 T AT223704 T AT 223704T
Authority
AT
Austria
Prior art keywords
method
wax matrices
producing wax
producing
matrices
Prior art date
Application number
AT93922628T
Other languages
German (de)
Inventor
Kouichi Nakamichi
Shougo Izumi
Hiroyuki Yasuura
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP30498692 priority Critical
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Priority to PCT/JP1993/001472 priority patent/WO1994008568A1/en
Publication of AT223704T publication Critical patent/AT223704T/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1694Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
AT93922628T 1992-10-16 1993-10-14 Method for producing wax matrices AT223704T (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP30498692 1992-10-16
PCT/JP1993/001472 WO1994008568A1 (en) 1992-10-16 1993-10-14 Method of manufacturing wax matrices

Publications (1)

Publication Number Publication Date
AT223704T true AT223704T (en) 2002-09-15

Family

ID=17939698

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93922628T AT223704T (en) 1992-10-16 1993-10-14 Method for producing wax matrices

Country Status (9)

Country Link
US (1) US5700410A (en)
EP (1) EP0665010B1 (en)
JP (1) JP2616252B2 (en)
AT (1) AT223704T (en)
AU (1) AU5160893A (en)
CA (1) CA2147283C (en)
DE (2) DE69332291T2 (en)
ES (1) ES2180548T3 (en)
WO (1) WO1994008568A1 (en)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69222847T3 (en) * 1991-04-16 2005-09-15 Nippon Shinyaku Co., Ltd. Process for preparing a solid dispersion
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
IL110014A (en) 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5879705A (en) 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
US5983956A (en) * 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
US5980949A (en) * 1994-10-03 1999-11-09 Astra Aktiebolag Formulation for inhalation
DE69432186D1 (en) * 1993-11-18 2003-04-03 Nippon Shinyaku Co Ltd Method for producing stable medicinal products
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
GB9422154D0 (en) 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
FR2729077B1 (en) * 1995-01-05 1997-02-21
SE9700133D0 (en) * 1997-01-20 1997-01-20 Astra Ab New formulation
SE9700135D0 (en) * 1997-01-20 1997-01-20 Astra Ab New formulation
DE69837903T2 (en) * 1997-08-11 2008-02-14 Pfizer Products Inc., Groton Solid pharmaceutical dispersions with increased bioavailability
US6524620B2 (en) 1998-07-20 2003-02-25 Andrx Pharmaceuticals, Inc. Diltiazem controlled release formulation and method of manufacture
US6106862A (en) * 1998-08-13 2000-08-22 Andrx Corporation Once daily analgesic tablet
US20020006438A1 (en) * 1998-09-25 2002-01-17 Benjamin Oshlack Sustained release hydromorphone formulations exhibiting bimodal characteristics
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
DE19918325A1 (en) 1999-04-22 2000-10-26 Euro Celtique Sa Extruded drug dosage form, e.g. granulate for tableting, comprising an active agent in a polysaccharide-containing matrix, giving a release profile which is controllable by extrusion conditions and/or the inclusion of additives
ITMI991316A1 (en) * 1999-06-14 2000-12-14 Cip Ninety Two 92 S A oral pharmaceutical compositions in modified release mesalazine
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
BR0015284B1 (en) 1999-10-29 2014-08-05 Euro-Celtique, S/A Controlled release hydrocodone formulations
DE10026698A1 (en) 2000-05-30 2001-12-06 Basf Ag Self-emulsifying drug formulation and use of this formulation
SE0003125D0 (en) * 2000-09-05 2000-09-05 Astrazeneca Ab Modified Polymers
EP1337244A4 (en) 2000-10-30 2006-01-11 Euro Celtique Sa Controlled release hydrocodone formulations
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
KR20130018960A (en) 2001-05-02 2013-02-25 유로-셀티크 소시에떼 아노뉨 Once-a-day oxycodone formulations
US7052706B2 (en) * 2001-06-08 2006-05-30 Nostrum Pharmaceuticals, Inc. Control release formulation containing a hydrophobic material as the sustained release agent
US7022342B2 (en) 2002-03-28 2006-04-04 Andrx Corporation, Inc. Controlled release oral dosage form of beta-adrenergic blocking agents
US20040005359A1 (en) * 2002-06-27 2004-01-08 Cheng Xiu Xiu Controlled release oral dosage form
US10004729B2 (en) 2002-07-05 2018-06-26 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
MXPA05000477A (en) * 2002-07-10 2005-03-23 Warner Lambert Co Combination of an allosteric inhibitor or matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib.
US6986901B2 (en) * 2002-07-15 2006-01-17 Warner-Lambert Company Llc Gastrointestinal compositions
US20040010035A1 (en) * 2002-07-15 2004-01-15 Ciociola Arthur A. Gastrointestinal compositions
EP1617838A4 (en) * 2003-04-25 2011-07-06 Mitsubishi Tanabe Pharma Corp Composition for oral administration containing alkylene dioxybenzene derivative
US7364755B2 (en) * 2003-07-07 2008-04-29 Synthon Ip Inc. Modified calcium phosphate excipient
US7314640B2 (en) * 2003-07-11 2008-01-01 Mongkol Sriwongjanya Formulation and process for drug loaded cores
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
GB0403098D0 (en) * 2004-02-12 2004-03-17 Euro Celtique Sa Extrusion
CA2916869A1 (en) 2004-06-12 2005-12-29 Jane C. Hirsh Abuse-deterrent drug formulations
US20060275367A1 (en) * 2005-04-25 2006-12-07 Shubha Chungi Extended release formulations
EP1933852B1 (en) * 2005-09-27 2018-12-19 TissueTech, Inc. Amniotic membrane preparations and purified compositions and methods of use
US8187639B2 (en) 2005-09-27 2012-05-29 Tissue Tech, Inc. Amniotic membrane preparations and purified compositions and anti-angiogenesis treatment
KR20120107533A (en) 2005-11-28 2012-10-02 마리누스 파마슈티컬스 Ganaxolone formulations and methods for the making and use thereof
CA2634059C (en) 2005-12-22 2015-11-24 Otsuka Pharmaceutical Co., Ltd. Method of producing drug-containing wax matrix particles, extruder to be used in the method and sustained-release preparation containing cilostazol
GB0600913D0 (en) * 2006-01-17 2006-02-22 Syngenta Ltd Improvements in or relating to organic compounds
US20070185065A1 (en) * 2006-02-03 2007-08-09 Vikramjit Chhokar Combination therapy for coronary artery disease
US20070243237A1 (en) * 2006-04-14 2007-10-18 Mazen Khaled Antimicrobial thin film coating and method of forming the same
EP2056818B1 (en) 2006-08-11 2011-05-25 The Johns Hopkins University Compositions and methods for neuroprotection
EA018573B1 (en) 2006-09-22 2013-09-30 Фармасайкликс, Инк. Inhibitors of bruton's tyrosine kinase
JP5411141B2 (en) 2007-09-10 2014-02-12 カルシメディカ,インク. Compounds that regulate intracellular calcium
KR101724161B1 (en) 2008-08-27 2017-04-06 칼시메디카, 인크 Compounds that modulate intracellular calcium
WO2010124296A2 (en) 2009-04-24 2010-10-28 Tissuetech, Inc. Compositions containing hc•ha complex and methods of use thereof
US7718662B1 (en) 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
WO2011090724A2 (en) * 2009-12-29 2011-07-28 Impax Laboratories, Inc. Gastroretentive solid oral dosage forms with lipid-based low-density excipient
WO2011130689A1 (en) 2010-04-15 2011-10-20 Tracon Pharmaceuticals, Inc. Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors
AU2011248579A1 (en) 2010-04-27 2012-11-29 Calcimedica, Inc. Compounds that modulate intracellular calcium
CA2797663C (en) 2010-04-27 2018-10-09 Calcimedica, Inc. Compounds that modulate intracellular calcium
EP2609095A4 (en) 2010-08-27 2014-06-18 Calcimedica Inc Compounds that modulate intracellular calcium
US9526770B2 (en) 2011-04-28 2016-12-27 Tissuetech, Inc. Methods of modulating bone remodeling
US9682044B2 (en) 2011-06-10 2017-06-20 Tissuetech, Inc. Methods of processing fetal support tissues, fetal support tissue powder products, and uses thereof
UA110853C2 (en) 2011-09-13 2016-02-25 Фармасайклікс, Інк. Dosage forms histone deacetylase inhibitor in combination with bendamustine and their use
US9364549B2 (en) * 2011-11-30 2016-06-14 Andreas Voigt Hydrophobic drug-delivery material, method for manufacturing thereof and methods for delivery of a drug-delivery composition
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
KR20150053753A (en) 2012-07-11 2015-05-18 티슈테크, 인코포레이티드 Compositions containing hc-ha/ptx3 complexes and methods of use thereof
EP2900674B1 (en) 2012-09-28 2017-05-31 University of Washington through its Center for Commercialization Compounds and methods for preventing, treating and/or protecting against sensory hair cell death
WO2014059333A1 (en) 2012-10-12 2014-04-17 Calcimedica, Inc. Compounds that modulate intracellular calcium
WO2015054283A1 (en) 2013-10-08 2015-04-16 Calcimedica, Inc. Compounds that modulate intracellular calcium
CN105960404B (en) 2013-12-05 2019-09-03 药品循环有限责任公司 The inhibitor of bruton's tyrosine kinase
WO2015164213A1 (en) 2014-04-23 2015-10-29 The Research Foundation For The State University Of New York A rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjuction therewith
TW201603818A (en) 2014-06-03 2016-02-01 組織科技股份有限公司 Compositions and methods
US9839644B2 (en) 2014-09-09 2017-12-12 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
US9359316B1 (en) 2014-11-25 2016-06-07 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
AU2016215023B2 (en) 2015-02-06 2019-12-19 Fred Hutchinson Cancer Research Center Compounds and methods for preventing or treating sensory hair cell death
US10227333B2 (en) 2015-02-11 2019-03-12 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
EP3297645A4 (en) 2015-05-20 2018-12-12 Tissuetech, Inc. Compositions and methods for preventing the proliferation and epithelial-mesenchymal transition of epithelial cells
EP3344254A1 (en) 2015-08-31 2018-07-11 Pharmacyclics LLC Btk inhibitor combinations for treating multiple myeloma
JP2019506387A (en) 2016-01-19 2019-03-07 ヤンセン ファーマシューティカ エヌ.ベー. Formulations / compositions containing BTK inhibitors
EP3405178A1 (en) 2016-01-19 2018-11-28 Janssen Pharmaceutica NV Formulations/compositions comprising a btk inhibitor
JP2019510826A (en) 2016-04-04 2019-04-18 シノピア バイオサイエンシーズ,インク. Treatment of extrapyramidal syndrome using trapidil
WO2017205762A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205769A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205766A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017222575A1 (en) 2016-06-23 2017-12-28 Collegium Pharmaceutical, Inc. Process of making more stable abuse-deterrent oral formulations

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2245640A (en) * 1936-04-10 1941-06-17 Tide Water Associated Oil Comp Method of molding paraffin wax
US4132753A (en) * 1965-02-12 1979-01-02 American Cyanamid Company Process for preparing oral sustained release granules
US3487138A (en) * 1966-11-23 1969-12-30 Merck & Co Inc Process for preparing a delayed release medicinal tablet
DE2426812A1 (en) * 1974-06-04 1976-01-02 Klinge Co Chem Pharm Fab A process for the preparation of granules
DE2426811A1 (en) * 1974-06-04 1976-01-08 Klinge Co Chem Pharm Fab A process for producing sustained-release tablets
DE2439538C3 (en) * 1974-08-17 1980-07-17 Ludwig Heumann & Co Gmbh, 8500 Nuernberg
FR2581541B1 (en) * 1985-05-09 1988-05-20 Rhone Poulenc Sante New pharmaceutical compositions for the sustained release of an active ingredient and method of preparing
EP0230647B1 (en) * 1985-12-27 1993-03-31 Sumitomo Pharmaceuticals Company, Limited Method for producing a sustained release formulation
DE3812567A1 (en) * 1988-04-15 1989-10-26 Basf Ag A process for preparing pharmaceutical mixtures
JP2893191B2 (en) * 1988-11-08 1999-05-17 武田薬品工業株式会社 Controlled release matrix dosage
AU645003B2 (en) * 1988-11-08 1994-01-06 Takeda Chemical Industries Ltd. Sustained release preparations
US5183690A (en) * 1990-06-25 1993-02-02 The United States Of America, As Represented By The Secretary Of Agriculture Starch encapsulation of biologically active agents by a continuous process
US5151026A (en) * 1990-10-31 1992-09-29 Werner & Pfleiderer Corp. Apparatus for removing liquids from solids
DE69222847T3 (en) * 1991-04-16 2005-09-15 Nippon Shinyaku Co., Ltd. Process for preparing a solid dispersion
DE4127665A1 (en) * 1991-08-22 1993-02-25 Beiersdorf Ag Galenic matrix
US5543099A (en) * 1994-09-29 1996-08-06 Hallmark Pharmaceutical, Inc. Process to manufacture micronized nifedipine granules for sustained release medicaments

Also Published As

Publication number Publication date
EP0665010A1 (en) 1995-08-02
AU5160893A (en) 1994-05-09
CA2147283C (en) 2007-01-16
CA2147283A1 (en) 1994-04-28
DE69332291T2 (en) 2003-07-31
EP0665010B1 (en) 2002-09-11
DE69332291D1 (en) 2002-10-17
WO1994008568A1 (en) 1994-04-28
US5700410A (en) 1997-12-23
JP2616252B2 (en) 1997-06-04
ES2180548T3 (en) 2003-02-16
EP0665010A4 (en) 1996-02-28
KR950703332A (en) 1995-09-20

Similar Documents

Publication Publication Date Title
DE69627642D1 (en) Method for producing paving
DE69530987D1 (en) Method for producing substituted sulfoxides
EG19392A (en) Improved method for omprazole symthesis
DE69526491D1 (en) Method for producing hollow microspheres
DE69632207D1 (en) Method for producing imidazochinolinamines
DE69625712T2 (en) Method for producing tetrahydroimidazochinolinamines
DE69635306D1 (en) Method for producing diode-modified polypropylene
DE69333823D1 (en) Method for producing members of specific binding savings
DE69719201D1 (en) Method for producing ecteinascidine compounds
DE69620461T2 (en) Method for producing 1,1,1,3,3, -pentafluoropropanes
DE69707702T2 (en) Method for producing vinyl acetate
DE69618020D1 (en) Method for producing hydrofluorethers
DE69621649T2 (en) Method for producing cefdinir
DE69711416D1 (en) Method for producing aethyl acetate
DE69334194D1 (en) Method for producing a semiconductor device
DK0589841T3 (en) Methods for producing hybrid seed
DE69627381D1 (en) Method for producing erythrmycine derivatives
DE69521915T2 (en) Method for producing etyhlbenzol or substituted derivatives thereof
DE59410076D1 (en) Method for producing caprolactam
DE69428280T2 (en) Method for producing azetidinones
HU9202135D0 (en) Method for producing heterocyclic compounds
AT443693T (en) Process for preparing substituted 1,1,1-trifluoro-3-butene-2-one
DE122010000051I1 (en) Method for producing surface modified nanoscale ceramic powder.
DE69726581D1 (en) Method for producing cyclohexandimethanol
PL300521A1 (en) Hydroformylation method

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties